SOURCE: Medistem Inc.

Medistem Inc.

June 26, 2013 09:00 ET

Medistem's Endometrial Regenerative Cell (ERC) Product Named as "Top 15 Promising Cell Therapies"

SAN DIEGO, CA--(Marketwired - Jun 26, 2013) - Medistem, Inc. (PINKSHEETS: MEDS) announced today that its clinical-stage stem cell product, the Endometrial Regenerative Cell (ERC), was named by the independent industry group Terrapinn as the "Top 15 Most Promising Stem Cell Therapies." The list was compiled after interviews with 200 experts from the field of regenerative medicine. The ranking was based on recent successful clinical data, effective capital formation strategies, stock history, personal recognition, and awareness across different markets. The report can be found at:

"Our Endometrial Regenerative Cell (ERC) product is the first clinical stem cell therapy derived from the lining of the uterus and collected from menstrual blood," said Alan Lewis, Ph.D., Chief Executive Officer of Medistem Inc. "The ease of collection of menstrual blood, ample donor population, and the fact that cells derived from one donor can generate 20,000 patient doses to treat unrelated recipients, are unique differentiating characteristics our product possesses."

In peer-reviewed publications, Medistem has published data demonstrating that its ERCs contain additional angiogenic and immune modulatory factors as compared to other adult stem cells.1 The National Institutes of Health has further independently verified this data.2 The Company is currently conducting a 60 patient double blind placebo controlled clinical trial for Congestive Heart Failure. Medistem has also received FDA clearance to commence a Critical Limb Ischemia trial, and is in late preclinical stage of development for Type 1diabetes.

Other companies and products that were also selected included Mesoblast's Mesenchymal Precursor Cells, Athersys's derived Multistem product, NeoStem's AMR-001, and Osiris Therapeutic's Prochymal®, all of which are adult bone marrow-derived stem cell products.

About Medistem, Inc.

Medistem, Inc. is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States. In January 2012, we announced the initiation of our RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) Phase II clinical trial. This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERCs in end stage CHF patients.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc. These can be identified by the use of forwardlooking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forward-looking statements. These forward-looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

1 Meng et al. J Transl Med. 2007 Nov 15;5:57.

2 Wang et al. J Transl Med. 2012 Oct 5;10:207.

Contact Information